Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AC ImmuneACIU +1.72%45 Debt-to-Equity is 0.12 as of Jun. 2026, which is 1100% above its 10-year median of 0.01. GuruFocus rates ACIU with a GF Score™ of 45/100 and a GF Value™ of $3.44 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 968 Biotechnology companies, AC Immune ranks better than 56.4% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for AC Immune's Debt-to-Equity or its related term are showing as below:
ACIU'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.01 Max: 0.2
Current: 0.12
During the past 12 years, the highest Debt-to-Equity Ratio of AC Immune was 0.20. The lowest was 0.00. And the median was 0.01.
ACIU's Debt-to-Equity is ranked better than 56.4% of 968
companies
in the Biotechnology industry
Industry Median: 0.16
vs ACIU: 0.12
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
AC Immune Debt-to-Equity Related Terms
AC Immune Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for AC Immune's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ACIU vs TRDA, TARA, SRZN: Debt-to-Equity Comparison
For the Biotechnology subindustry, AC Immune's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AC Immune Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, AC Immune's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where AC Immune's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AC Immune (ACIU) has a Debt-to-Equity of 0.12 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on AC Immune and its competitors. This is 1100% above median its historical median of 0.01. According to the industry distribution chart, AC Immune ranks #422 out of 968 companies in the Biotechnology industry, placing it in the top 43.6%.
Is AC Immune's Debt-to-Equity too high?
AC Immune's current Debt-to-Equity of 0.12 is 1100% above median its 10-year median of 0.01. The Biotechnology industry median Debt-to-Equity is 0.16. AC Immune's value of 0.12 is 25% below this industry median. Based on the distribution chart, AC Immune ranks #422 out of 968 companies in the Biotechnology industry, which is above the industry midpoint. Overall, AC Immune has a GF Score™ of 45/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does AC Immune's Debt-to-Equity compare to TRDA and TARA?
According to the Biotechnology industry distribution chart, AC Immune ranks #422 out of 968 companies for Debt-to-Equity. This puts AC Immune in the upper half of its industry. The industry median Debt-to-Equity is 0.16. AC Immune's value of 0.12 is 25% below this benchmark. While the company's 10-year median is 0.01 vs. the industry median of 0.16, AC Immune has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 968 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AC Immune's current Debt-to-Equity of 0.12 is 25% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on AC Immune and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AC Immune's current Debt-to-Equity is 0.12, which is 1100% above median its own 10-year median of 0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AC Immune stock overvalued right now?
Based on GuruFocus' analysis, AC Immune (ACIU) is currently considered Possible Value Trap. The stock's GF Value™ is $3.44, compared to a current price of $2.35 — trading 31.7% below its estimated fair value. The current Debt-to-Equity is 0.12, which is 1100% above median its 10-year median of 0.01 and 25% below the Biotechnology industry median of 0.16. AC Immune's overall GF Score™ is 45/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For AC Immune (ACIU), the current Debt-to-Equity is 0.12 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AC Immune (ACIU) Overvalued in 2026?
Based on GuruFocus' analysis, AC Immune stock appears to be undervalued.
The current stock price of $2.35 is trading 31.7% below its estimated GF Value™ of $3.44.
GuruFocus considers AC Immune to be Possible Value Trap.
Key valuation signals for ACIU:
Debt-to-Equity: 0.12 (1100% above median its 10-year median of 0.01)
GF Value™: $3.44 vs. price of $2.35 (31.7% below fair value)
Industry Position: 25% below the Biotechnology median (#422 of 968)
No single metric tells the full story. See the ACIU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
45GF Score
Get the complete analysis for ACIU
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ACIU has been successfully added to your 
